Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech companies in the UK, Europe and USA...

Nelson Advisors invited to judge the Fast Pitch Awards at the Healthcare Summit 2025 Nelson Advisors partners Lloyd Price and Paul...

Nelson Advisors featured in the PMLiVE article 'The digital prescription: enhancing the patient experience with technology' Nelson...

Nelson Advisors thought leadership blog 'Healthcare.Digital' has featured in the Tony Blair Institute for Global Change publication 'The NHS at a Crossroads: The App That Can Transform Britain’s Health' highlighting the scale and importance of Doctolib in the French HealthTech market.

The healthcare industry is in the midst of a profound transformation, driven by the convergence of digital platforms, a growing abundance of health data, and the analytical power of artificial intelligence (AI). This shift is not merely an incremental improvement but a fundamental re-architecture of care delivery, moving toward models that are more proactive, personalised, and efficient. The market for these technologies is expanding at an unprecedented rate, creating a clear

The speculative "gold rush" in healthcare artificial intelligence, characterised by a feverish pace of unbridled investment and a technology-first approach to product development, has concluded. A new, more discerning market has emerged, defined not by the promise of an algorithm but by a strategic fusion of technological efficacy, market access, and quantifiable value. This report provides a detailed analysis of this new equilibrium. The distinction between "thrivers" an

The MedTech sector in 2026 stands at a pivotal juncture, defined by the convergence of rapid technological innovation, a maturing market demanding proven value, and a complex policy landscape. This report synthesizes these forces, moving from a macro-level analysis to specific, actionable insights. The industry is shifting from a focus on siloed technological advancements to an integrated, interconnected ecosystem where success hinges on the ability to operationalise innovati

The analysis of Nelson Advisors reveals a sophisticated and highly specialised boutique investment banking firm whose value proposition is built on a unique confluence of expertise. The firm's exclusive focus on the European HealthTech sector is a powerful competitive differentiator, allowing it to provide a level of nuanced, industry-specific advisory that generalist firms cannot match. The "Founders for Founders" approach, which is the cornerstone of its identity, is a stra

OpenAI GPT-5: Strategic Potential in Healthcare Executive Summary: GPT-5's Strategic Potential in Healthcare OpenAI's GPT-5 represents a...

The ambient clinical intelligence (ACI) market is at a critical inflection point, transitioning from an innovative, startup-driven ecosystem to a landscape dominated by powerful platform players. For years, a crowded field of digital health companies has addressed the profound problem of physician burnout by developing AI scribes that automate clinical documentation. However, this competitive dynamic is now being fundamentally reshaped by the entry of two dominant forces: the

The recent initial public offering (IPO) of HeartFlow represents a significant milestone in the convergence of artificial intelligence (AI) and medical technology. The company, which is focused on diagnosing and managing coronary artery disease (CAD), successfully navigated a challenging market to complete a landmark public debut on the Nasdaq Global Select Market under the ticker symbol HTFL. The offering was met with robust investor demand, leading to a significant increase

In an era of accelerated technological change, the healthcare technology (healthtech) sector stands at a unique and complex intersection. Unlike conventional industries, healthtech operates in a domain where the stakes extend beyond market share to encompass patient safety, clinical efficacy, and systemic trust. The traditional benchmark of success, "product-market fit," is therefore a necessary but fundamentally insufficient measure for a healthtech venture.

Hinge Health (NYSE: HNGE) has demonstrated a remarkable post-Initial Public Offering (IPO) performance, with its share price surging approximately 56% since its market debut in May 2025. This significant appreciation reflects robust investor confidence, driven by strong financial results and strategic advancements within the digital musculoskeletal (MSK) care market. The company's first quarterly earnings report as a public entity for Q2 2025 showcased substantial revenue

Photobiomodulation (PBM), a non-invasive therapeutic modality utilising specific wavelengths of light, is emerging as a significant healthtech to watch in 2026. Its fundamental action involves stimulating cellular metabolism by enhancing mitochondrial function, which in turn reduces inflammation, promotes tissue repair, and alleviates pain. While already established in areas such as pain management, wound healing, and oral mucositis, PBM is demonstrating remarkable potential

The MIT Technology Review Insights report, "Scaling integrated digital health," sponsored by Roche, illuminates a compelling paradox within the global healthcare sector. While an overwhelming 96% of healthcare executives express readiness and possess resources for digital health solutions, this enthusiasm is tempered by significant, though perceived as manageable, systemic challenges. The most prominent of these challenges centers on interoperability, with 91% of executives a